The Pharmacy Times® Mental Health Resource Center is a comprehensive resource for clinical news and expert insights on conditions that affect mood, thinking, and behavior, including clinical depression, bipolar disorder, schizophrenia, anxiety, and post-traumatic stress disorder.
July 31st 2025
Pharmacists guide pregnant women in balancing depression treatment with SSRI safety, addressing risks of untreated depression and neonatal adaptation syndrome.
FDA OKs Esketamine Nasal Spray for Treatment-Resistant Depression
March 6th 2019Once Spravato is determined as an appropriate treatment option, in accordance with the REMS, the patient will be treated at a certified treatment center that is trained to administer the medicine and address patient needs.
Read More
FDA Updates Fluoroquinolone Labeling to Strengthen Mental Health, Hypoglycemia Risks
July 11th 2018Officials with the FDA are requiring safety label updates for fluoroquinolone antibiotics due to risks of mental health adverse effects and blood sugar disturbances, according to a press release
Read More
FDA Issues Safety Warning for Drug That Treats Seizures, Bipolar Disorder
April 26th 2018Lamotrigine (Lamictal) for seizures and bipolar disorder can cause hemophagocytic lymphohistiocytosis (HLH), a rare, but very serious immune system reaction that excessively activates the body’s infection-fighting immune system.
Read More
FDA OKs Lurasidone for Use as Bipolar Medication in Children
March 7th 2018Officials with the FDA have approved a supplemental new drug application (sNDA) to expand the use of lurasidone HCl (Latuda, Sunovion) to include the treatment of bipolar depression in pediatric patients (10 to 17 years of age).
Read More
Perinatal HIV Infection: Nonadherence Risk Increases in Adolescents
December 15th 2017Adolescents and young adults who are living with HIV and were exposed to the virus perinatally have a unique risk of nonadherence in adolescence, as well as an elevated risk of mental health and substance use problems.
Read More